

DAFTAR PUSTAKA

1. Widiatmoko A, Brahmanti H, Padesa TPB. Combination of Excision Surgery , Intralesional Corticosteroid Injection and Silicone Gel in Management of Earlobe Keloid. MDVI. 2019;46(2):87–91.
2. Sun LM, Wang KH, Lee YCG. Keloid incidence in Asian people and its comorbidity with other fibrosis-related diseases: a nationwide population-based study. Arch Dermatol Res. 2014;306(9):803–8.
3. Andisi RDS, Suling PL, Kapantow MG. Profil keloid di Poliklinik Kulit dan Kelamin RSUP Prof. Dr. R. D. Kandou Manado periode Januari 2011-Desember 2015. e-CliniC. 2016;4(2).
4. Birawati S, Asri E. Keloids Profile in the Dermatovenerology Clinic of RSUP Dr. M. Djamil Padang Indonesia from January 2014 to December 2018. Int J Pharmtech Res. 2020;13(4):383–7.
5. Kassi K, Kouame K, Kouassi A, Allou A, Kouassi I, Kourouma S, et al. Quality of life in black African patients with keloid scars. Dermatol Reports. 2020 Oct 22;12(2):28–31.
6. Bijlard E, Kouwenberg CAE, Timman R, Hovius SER, Busschbach JJV, Mureau MAM. Burden of keloid disease: A cross-sectional health-related quality of life assessment. Acta Derm Venereol. 2017 Feb 1;97(2):225–9.
7. Lu W, Chu H, Zheng X. Effects on quality of life and psychosocial wellbeing in Chinese patients with keloids. Am J Transl Res [Internet]. 2021;13(3):1636–42. Available from: <http://www.de>
8. Unahabhokha T, Sucontphunt A, Nimmannit U, Chanvorachote P, Yongsanguanchai N, Pongrakhananon V. Molecular signalings in keloid disease and current therapeutic approaches from natural based compounds. Vol. 53, Pharmaceutical Biology. Informa Healthcare; 2015. p. 457–63.
9. Kurniawati Y, Suwarsa O, Agung A, Adi S. The Comparison of the Levels of Leukotriene B4, TGF- β 1, Collagen in Keloid Fibroblasts and Normal Skin Fibroblast. OAlib. 2016;03(07):1–7.
10. Amsen D, de Visser KE, Town T. Approaches to determine expression of inflammatory cytokines. Methods Mol Biol. 2009;511:107–42.
11. Arno AI, Gauglitz GG, Barret JP, Jeschke MG. Up-to-date approach to manage keloids and hypertrophic scars: A useful guide. Burns [Internet]. 2014;40(7):1255–66. Available from: <http://dx.doi.org/10.1016/j.burns.2014.02.011>
12. Perdanasari AT, Lazzeri D, Su W, Xi W, Zheng Z, Ke L, et al. Recent developments in the use of intralesional injections keloid treatment. Arch Plast Surg. 2014;41(6):620–9.
13. Thornton NJ, Garcia BA, Hoyer P, Wilkerson MG. Keloid Scars: An Updated Review of Combination Therapies. Cureus. 2021 Jan 30;13(1).
14. Mansyah E, Muas I, Jawal MA. Morphological Variability of Apomictic Mangosteen (*Garcinia mangostana* L.) in Indonesia: Morphological Evidence of Natural Populations from Sumatra And Java. SABRAO J Breed Genet. 2010;42(1):1–8.
15. Irfan Z. Profil Usahatani Manggis Pada Tiga Daerah Sentra Produksi Di Sumatera Barat. Prosiding Seminar Nasional Hortikultura. Padang; 2010.
16. Muchtaridi M, Wijaya CA. Anticancer potential of α -mangostin. Asian Journal of Pharmaceutical and Clinical Research. 2017;10(12):440–5.

17. Melia S, Novia D, Juliyarsi I, Purwati E. The characteristics of the pericarp of *garcinia mangostana* (mangosteen) extract as natural antioxidants in rendang. In: IOP Conference Series: Earth and Environmental Science. Institute of Physics Publishing; 2019.
18. Menteri Kesehatan Republik Indonesia. Peraturan Menteri Kesehatan Republik Indonesia Nomor 6 Tahun 2016 Tentang Formularium Obat Herbal Asli Indonesia. Jakarta; 2016.
19. Rizaldy D, Hartati R, Nadhifa T, Fidrianny I. Chemical compounds and pharmacological activities of mangosteen (*Garcinia mangostana* L.)-updated review. Vol. 12, Biointerface Research in Applied Chemistry. AMG Transcend Association; 2022. p. 2503–16.
20. Zhang KJ, Gu QL, Yang K, Ming XJ, Wang JX. Anticarcinogenic Effects of α -Mangostin: A Review. *Planta Med.* 2017 Feb 1;83(3–4):188–202.
21. Ibrahim MY, Hashim NM, Mariod AA, Mohan S, Abdulla MA, Abdelwahab SI, et al. α -Mangostin from *Garcinia mangostana* Linn: An updated review of its pharmacological properties. Vol. 9, *Arabian Journal of Chemistry*. Elsevier B.V.; 2016. p. 317–29.
22. Kritsanawong S, Innajak S, Imoto M, Watanapokasin R. Antiproliferative and apoptosis induction of α -mangostin in T47D breast cancer cells. *Int J Oncol.* 2016;48(5):2155–65.
23. Rahmaniah R, Yuyuntia Y, Soetikno V, Arozal W, Antarianto RD, Louisa M. Alpha mangostin Inhibits Hepatic Stellate Cells Activation Through TGF- β /Smad and Akt Signaling Pathways: An in vitro Study in LX2. *Drug Res.* 2018;68(3):153–8.
24. Lestari N, Louisa M, Soetikno V, Suwana AG, Ramadhan PA, Akmal T, et al. Alpha Mangostin Inhibits the Proliferation and Activation of Acetaldehyde Induced Hepatic Stellate Cells through TGF- β and ERK 1/2 Pathways. *J Toxicol [Internet]*. 2018;2018. Available from: <https://pubmed.ncbi.nlm.nih.gov/30538742>
25. Adenina S, Rahmaniah, Yuyuntia, Soetikno V, Louisa M. The Effect of Alpha-Mangostin on Transforming Growth Factor Beta 1 (TGF- β 1) and Matrix Metalloproteinase-3 Expression In TGF- β 1-Induced Hepatic Stellate Cells. *International Journal of Applied Pharmaceutics.* 2019;177–80.
26. Adenina S, Louisa M, Soetikno V, Arozal W, Wanandi SI. The effect of alpha mangostin on epithelial-mesenchymal transition on human hepatocellular carcinoma HepG2 cells surviving sorafenib via TGF- β /smad pathways. *Adv Pharm Bull.* 2020;10(4):648–55.
27. Supp DM, McFarland KL, Hahn JM, Combs KA. 140 Alpha-Mangostin Inhibits Proliferation, Promotes Apoptosis, and Modulates Fibrotic Gene Expression in Normal and Keloid Fibroblasts In Vitro. *Journal of Burn Care & Research [Internet]*. 2021;42:93–4. Available from: <https://doi.org/10.1093/jbcr/irab032.144>
28. Huang C, Liu L, You Z, Wu Z, Du Y, Ogawa R. Clinical and Pathological Diagnosis of Scars. In: Ogawa R, editor. *Total Scar Management: From Lasers to Surgery for Scars, Keloids, and Scar Contractures [Internet]*. Singapore: Springer Singapore; 2020. p. 83–95. Available from: https://doi.org/10.1007/978-981-32-9791-3_7
29. Kouotou EA, Nansseu JR, Omona Guissana E, Mendouga Menye CR, Akpadjan F, Tounkara TM, et al. Epidemiology and clinical features of keloids in Black Africans: a nested case–control study from Yaoundé, Cameroon. *Int J Dermatol.* 2019;58(10):1135–40.
30. Wardani FA, Perdanakusuma DS, Indramaya DM. Profile of Working-Age Patients with Keloid and Hypertrophic Scar at Dr. Soetomo General Hospital Surabaya in

- 2014-2017. *JUXTA: Jurnal Ilmiah Mahasiswa Kedokteran Universitas Airlangga*. 2021 Aug 31;12(2):77.
31. Limandjaja GC, Niessen FB, Scheper RJ, Gibbs S. Hypertrophic scars and keloids: Overview of the evidence and practical guide for differentiating between these abnormal scars. *Exp Dermatol*. 2020;(December 2019):1–16.
 32. Ogawa R. *Total Scar Management*. Ogawa R, editor. Springer; 2020.
 33. Shaheen AA. Risk Factors of Keloids: A Mini Review. *Austin Journal of Dermatology*. 2017;4(2).
 34. Manoharan A, Rao SM. Analysis of risk factors behind keloid. *International Journal of Research in Dermatology*. 2020;6(2):138.
 35. Hsu CK, Yang HS, McGrath J. Genetics of Scars and Keloids. In: Ogawa R, editor. *Total Scar Management*. Singapore: Springer; 2020. p. 47–53.
 36. Ojeh N, Bharatha A, Gaur U, Forde AL. Keloids: Current and emerging therapies. *Scars Burn Heal*. 2020;6.
 37. Nangole FW, Agak GW. Keloid pathophysiology: fibroblast or inflammatory disorders?: Pathophysiology of Keloids. Vol. 22, *JPRAS Open*. Elsevier Ltd; 2019. p. 44–54.
 38. Wang Z cai, Zhao W yi, Cao Y, Liu Y qi, Sun Q, Shi P. The Roles of Inflammation in Keloid and Hypertrophic Scars. 2020;11(December):1–10.
 39. Alavi A, Kirsner RS. Wound Healing. In: Kang S, Amagai M, Bruckner AL, Enk AH, Margolis DJ, McMichael AJ, et al., editors. *Fitzpatrick's Dermatology*, 9e [Internet]. New York, NY: McGraw-Hill Education; 2019. Available from: accessmedicine.mhmedical.com/content.aspx?aid=1161351153
 40. Limandjaja GC, Niessen FB, Scheper RJ, Gibbs S. Hypertrophic scars and keloids: Overview of the evidence and practical guide for differentiating between these abnormal scars. Vol. 30, *Experimental Dermatology*. Blackwell Publishing Ltd; 2021. p. 146–61.
 41. Xu F, Liu C, Zhou D, Zhang L. TGF- β /SMAD Pathway and Its Regulation in Hepatic Fibrosis. *Journal of Histochemistry and Cytochemistry*. 2016;64(3):157–67.
 42. Tripathi S, Soni K, Agrawal P, Gour V, Mondal R, Soni V. Hypertrophic scars and keloids: a review and current treatment modalities. *Biomedical Dermatology*. 2020 Dec;4(1).
 43. Kilmister EJ, Paterson C, Brasch HD, Davis PF, Tan ST. The Role of the Renin-Angiotensin System and Vitamin D in Keloid Disorder—A Review. *Front Surg*. 2019;6:1–12.
 44. Yoo MG, Kim IH. Keloids and hypertrophic scars: Characteristic vascular structures visualized by using dermoscopy. *Ann Dermatol*. 2014;26(5):603–9.
 45. Abdallah M, Yassin M, Saber N. Dermoscopic Features of Keloid versus Hypertrophic Scar. *Egypt J Hosp Med*. 2018;70(4):621–4.
 46. Jumper N, Paus R, Bayat A. Functional histopathology of keloid disease. *Histol Histopathol*. 2015;30(9):1033–57.
 47. Lee HJ, Jang YJ. Recent understandings of biology, prophylaxis and treatment strategies for hypertrophic scars and keloids. *Int J Mol Sci*. 2018;19(3).
 48. Betarbet U, Blalock TW. Keloids: A Review of Etiology, Prevention, and Treatment. *J Clin Aesthet Dermatol*. 2020;13(2):33–43.
 49. Ye Q, Wang SJ, Chen JY, Rahman K, Xin HL, Zhang H. Medicinal plants for the treatment of hypertrophic scars. *Evidence-based Complementary and Alternative Medicine*. 2015;2015.
 50. Ti YL, Song F, Fang Z, Zhang P. Plants and phytochemicals inhibit scar formation: A systematic review. *Ind Crops Prod*. 2022;185.

51. Febrina D, Milanda T, Muchtaridi. Pharmacological Activity *Garcinia mangostana* linn: a review. *International Journal of Current Medical Sciences* [Internet]. 2018;8(5):430–3. Available from: <https://www.researchgate.net/publication/326402947>
52. Achmadi SS. Polyphenols Resources in Indonesia From Economic Perspective. *Polyphenols in Plants*. 2019;67–79.
53. Rohman A, Arifah FH, Irnawati, Alam G, Muchtaridi, Rafi M. A review on phytochemical constituents, role on metabolic diseases, and toxicological assessments of underutilized part of *Garcinia mangostana* L. fruit. *J Appl Pharm Sci*. 2020;10(7):127–46.
54. Ghasemzadeh A, Jaafar HZE, Baghdadi A, Tayebi-Meigooni A. Alpha-mangostin-rich extracts from mangosteen pericarp: Optimization of green extraction protocol and evaluation of biological activity. *Molecules*. 2018;23(8).
55. Rubiyanti R, Susilawati Y, Muchtaridi M, Kunci K, buah manggis K, mangostana GL, et al. Potensi Ekonomi Dan Manfaat Kandungan Alfa-Mangostin Serta Gartnerin dalam Kulit Buah Manggis (*Garcinia mangostana* Linn). *Farmaka*. 2017;15(1):15–25.
56. Wang MH, Zhang KJ, Gu QL, Bi XL, Wang JX. Pharmacology of mangostins and their derivatives: A comprehensive review. Vol. 15, *Chinese Journal of Natural Medicines*. China Pharmaceutical University; 2017. p. 81–93.
57. Jittiporn K, Suwanpradid J, Patel C, Rojas M, Thirawarapan S, Moongkarndi P, et al. Anti-angiogenic actions of the mangosteen polyphenolic xanthone derivative α -mangostin. *Microvasc Res* [Internet]. 2014;93:72–9. Available from: <https://www.sciencedirect.com/science/article/pii/S0026286214000600>
58. Kaomongkolgit R. Alpha-mangostin suppresses MMP-2 and MMP-9 expression in head and neck squamous carcinoma cells. *Odontology* [Internet]. 2013;101(2):227–32. Available from: <https://doi.org/10.1007/s10266-012-0081-2>
59. Wang F, Ma H, Liu Z, Huang W, Xu X, Zhang X. α -Mangostin inhibits DMBA/TPA-induced skin cancer through inhibiting inflammation and promoting autophagy and apoptosis by regulating PI3K/Akt/mTOR signaling pathway in mice. *Biomedicine and Pharmacotherapy*. 2017 Aug 1;92:672–80.
60. Ud-Din S, Bayat A. Non-animal models of wound healing in cutaneous repair: In silico, in vitro, ex vivo, and in vivo models of wounds and scars in human skin. *Wound Repair and Regeneration*. 2017 Mar 1;25(2):164–76.
61. Khumairoh I, Puspitasari IM, Raya Bandung-Sumedang km J. *Kultur sel*. *Farmaka*. 2016;14(2):98–109.
62. Lio TMP, Sanatang, Aldiana, al et, *Penelitian Biologi J*. Pengaruh Waktu Penyimpanan Sampel Serum Terhadap Kuantitas dan Kualitas DNA: 44 Pengamatan Selama 1 Tahun Pengaruh Waktu Penyimpanan Sampel Serum Terhadap Kuantitas dan Kualitas DNA: Pengamatan Selama 1 Tahun. *BioWallacea : Jurnal Penelitian Biologi (Journal of Biological Research)*. 2021;8(1):44–51.
63. Yazarlu O, Iranshahi M, Kashani HRK, Reshadat S, Habtemariam S, Iranshahy M, et al. Perspective on the application of medicinal plants and natural products in wound healing: A mechanistic review. *Pharmacol Res*. 2021;174.
64. Siriwattanasatorn M, Itharat A, Thongdeeying P, Oraikul B. In Vitro Wound Healing Activities of Three Most Commonly Used Thai Medicinal Plants and Their Three Markers. *Evidence-based Complementary and Alternative Medicine*. 2020;2020.

65. Patrick M, Zohdi WNWM, Muid SA, Omar E. Alpha-mangostin(*Garcinia mangostana* Linn.) and its potential application in mitigating chronic wound healing. *Malaysian Applied Biology*. 2022 Jun 1;51(2):1–8.

